Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Actually, technically, it is a "partnership" in NAME only.

No offense, but I don't think you truely understood what I wrote... No one has mentioned any interest to "disolve from TPL". TPL has an ownership interest, the MMP is and will remain jointly owned. What TPL has that we don't, is "Operational control". TPL has control of the MMP, I want to take that away from them and give it to us. Do you understand the difference between "ownership" and "control" ?

That said, you apparently agree that TPL should be marginalized because you write... "I'd welcome any discussion HOW we can strengthen our company as controlling and acting power of this tripartite "partnership". So.. I officially welcome to group :)

For anyone to accept the current disparity of authority between the partners is to accept the status quo, and a continually underperforming and depressed PTSC stock price; regardless of what the actual price trades for. We now know that PTSC's passive and subservient relationship with TPL will always be depressive to our stock price.

The HTC trial was great victory for the MMP technology, it was also a display of the unexcusable failures of TPL to establish integrity in our Licensing program and to develop trustfulness in our representations which leads to efficient and credible cooperative licensing.

5
Oct 08, 2013 10:16PM
Share
New Message
Please login to post a reply